. Physostigmine results in an increased decrement in brain glucose consumption in Alzheimer's disease. Psychopharmacology (Berl). 1998 Apr;136(3):256-63. PubMed.

Recommends

Please login to recommend the paper.

Comments

  1. This paper suggests that the weak clinical response of AD patients to cholinergic agents may be due to cholinergic depression of glucose consumption. Alternative explanations may also be possible.

Make a Comment

To make a comment you must login or register.